Moleculin Biotech (NASDAQ:MBRX) Stock Rating Reaffirmed by Roth Mkm

Roth Mkm reiterated their buy rating on shares of Moleculin Biotech (NASDAQ:MBRX) in a research note released on Friday, Benzinga reports. They currently have a $40.00 target price on the stock.

Several other equities analysts have also weighed in on the company. HC Wainwright restated a buy rating and issued a $45.00 price target on shares of Moleculin Biotech in a research note on Thursday, December 14th. Maxim Group cut their price target on Moleculin Biotech from $45.00 to $20.00 and set a buy rating for the company in a research note on Tuesday, March 26th. Finally, StockNews.com started coverage on Moleculin Biotech in a report on Friday, April 5th. They issued a sell rating on the stock.

Moleculin Biotech Stock Down 3.6 %

Shares of Moleculin Biotech stock opened at $4.46 on Friday. Moleculin Biotech has a twelve month low of $4.32 and a twelve month high of $24.75. The business has a 50-day moving average price of $7.26 and a 200 day moving average price of $8.17. The firm has a market cap of $9.95 million, a PE ratio of -0.33 and a beta of 1.96.

Institutional Investors Weigh In On Moleculin Biotech

Several institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. acquired a new position in shares of Moleculin Biotech during the 4th quarter worth approximately $39,000. Atticus Wealth Management LLC acquired a new position in shares of Moleculin Biotech during the 4th quarter worth approximately $43,000. Citadel Advisors LLC acquired a new position in shares of Moleculin Biotech during the 4th quarter worth approximately $55,000. Renaissance Technologies LLC boosted its holdings in shares of Moleculin Biotech by 34.7% during the 2nd quarter. Renaissance Technologies LLC now owns 127,400 shares of the company’s stock worth $74,000 after purchasing an additional 32,795 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of Moleculin Biotech by 19.2% during the 1st quarter. State Street Corp now owns 71,397 shares of the company’s stock worth $127,000 after purchasing an additional 11,497 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.